A next-generation pesticide designed to kill crop pests may also be interfering with the reproductive health of bumblebees. Researchers discovered that low-dose exposure to sulfoxaflor changed gene activity, especially in tissues involved in reproduction, raising concerns about long-term impacts on bee populations. Because pollinators are essential for about one-third of the world's food production, finding ways to protect them while controlling pests has become increasingly important.Bumblebees

Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). Jascayd is the first treatment of its kind licensed for use in IPF and PPF in adults. The MHRA authorisation is based on the results of the pivotal phase 3 clinical trials involving 1,177 and 1,176 patients with IPF and PPF re

Under the agreement, researchers plan to use Apertura’s TfR1 CapX adeno-associated virus capsid. Credit: H_Ko / Shutterstock.com. Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1). The company signed the agreement to test the investigational therapy with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Human Genome Researc

iStock, nadia_bormotova Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx. The pressure on Amgen’s Tavneos is ratcheting up ahead of a potential hearing about the future of the drug. Since the FDA proposed withdrawing approval in April, a journal has retracted a key paper on

Sarclisa Escena administered via the CirCLIQ® on-body injector (OBI) offers a treatment experience designed with patients and HCPs in mind The first anticancer treatment to be administered through an OBI, and the first MM treatment available by both SC OBI and manual SC administration in the US Efficacy of Sarclisa now available in SC formulation with innovative OBI across approved combinations and lines of therapy Paris, July 10, 2026. The US Food and Drug Administration (FDA) has approved subc

Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leadi

Global CRO highlights multi-regional trial delivery, early-phase Australia advantages, and expanding support for biotech sponsors across Asia and China ADELAIDE, Australia, July 10, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced its participation in BIO Asia–Taiwan 2026 , taking place 15–19 July at the Taipei Nangang Exhibition Center (TaiNEX), Taipei. The event underscores Avance Clinical’s contin

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common st

This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) is pleased to announce that Canada’s Drug Agency (CDA) has issued a positive reimbursement recommendation with conditions for PrEMPAVELI ® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 years and older with C3 glomerulopathy (C3G) or primary im

Today, a brief rundown of news involving ARPA-H and Biohaven, as well as updates from Tarsus Pharmaceuticals, Ipsen and Scipher Medicine that you may have missed.The Advanced Research Projects Agency for Health, or ARPA-H, is awarding $160 million over a five-year period to a group of organizations and institutions working on personalized treatments for rare genetic conditions. The agencys THRIVE program is meant to help accelerate these kinds of bespoke treatments by essentially pioneering clin